#	Pagina
attuale pagina	/open-h2020/projects/198562/index.html

Opendata, web and dolomites

EPIGEN

EPIGEN: A New Predictive Response Test for Non Small Cells Lung Cancer Treatment

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

EPIGEN project word cloud

Explore the words cloud of the EPIGEN project. It provides you a very rough idea of what is the project "EPIGEN" about.

chain avoiding polymerase qms reagents percentage epigen treatments tecnology unnecesary resistance ready smal therapies standar radio extended treatment susceptibility lung igfbp oncologist tumor cell chemotherapy subtype determined 65 80 tecnique costly biomarker samples pcr nsclc combat clinician cancer personalyzed predict radiotharapy protocol chemo patient prescription biochemistry patients optimal stratification tool methylation radiotherapy epigenetic quantitative

Project "EPIGEN" data sheet

The following table provides information about the project.

Coordinator	IGEN BIOTECH SL Organization address address: CALLE GUSTAVO FERNANDEZ BALVUENA 11 city: MADRID postcode: 28002 website: www.igenbiotech.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Project website	http://www.igenbiotech.com/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2015
Funding Scheme	SME-1
Starting year	2015
Duration (year-month-day)	from 2015-09-01 to 2015-10-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	IGEN BIOTECH SL IGEN BIOTECH SL Organization address address: CALLE GUSTAVO FERNANDEZ BALVUENA 11 city: MADRID postcode: 28002 website: www.igenbiotech.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (MADRID)	coordinator	50˙000.00

Map

Project objective

EPIGEN test is a ready-to-use tool capable to lead the oncologist to the best Non Smal Cell Lung Cancer treatment, the most common subtype of lung cancer (80% of cases). The standar treatments to combat NSCLC are both chemo- and radiotherapy, but many patients (up to 65%) presents resistance, and currently there is not any tool available for the clinician to predict it. The EPIGEN test will allow the clinician a patient stratification in terms of the patient susceptibility to radio- and chemotherapy, and therefore lead for a personalyzed prescription. The EPIGEN test tecnology is based on the determination of the methylation percentage of the epigenetic biomarker IGFBP-3 in the patient tumor samples. The methylation percentage of IGFBP-3 is determined by using qMS-PCR (quantitative methylation specific polymerase chain) tecnique, a well known and extended biochemistry tecnique. The methylation percentage provided by using the EPIGEN test protocol and reagents in the qMS-PCR tecnique will lead the clinician for the optimal NSCLC treatment, avoiding the possible patient resistance to chemo and radiotharapy, and therefore unnecesary side effects and costly therapies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPIGEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPIGEN" are provided by the European Opendata Portal: CORDIS opendata.